share_log

Modalis Therapeutics Partners With Ginkgo Bioworks, Enhancing Cell And Gene Therapy With CRISPR-GNDM Technology

Benzinga ·  Apr 12 15:10

Modalis Joins Ginkgo's Technology Network

Modalis Therapeutics Corporation (Modalis) (Tokyo Stock Exchange: 4883) announced that it has entered into an agreement with Ginkgo Bioworks (Ginkgo) to join the Ginkgo Technology Network. This strategic alliance will enable Ginkgo's global customers in the cell and gene therapy fields to access Modalis' proprietary epigenome modulation technology, CRISPR-GNDM (Guide Nucleotide-Directed Modulation). Modalis' CRISPR-GNDM Technology is capable of activating or suppressing any gene in a controlled manner without requiring DNA cleavage. This collaboration also creates a significant opportunity for Modalis to establish additional strategic partnerships.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment